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Abstract: The astonishing speed with which Dengue has spread across the world and the severity of its infection make 
Dengue a prime threat to human life worldwide. Unfortunately, to date there are no effective vaccines or treatments 
against Dengue. Since only a few assays permit rapid and sensitive detection of Dengue, we developed a specific antigen 
capture enzyme-linked immunosorbent assay (ELISA) for the abundant structural Dengue-2 capsid protein. We showed 
that the ELISA allows rapid and sensitive detection of Dengue-2 replication in various cell lines including human and 
mosquito cells. Using anti-capsid antibodies, we demonstrated that the capsid ELISA is as accurate as other well-
characterized Dengue assays such as intracellular FACS staining (IFSA) and fluorescent focus (FFA) assays. The capsid 
ELISA not only represents a useful tool for in vitro basic research, but it may also represent a valuable diagnostic tool for 
Dengue infection in patients. 
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1. INTRODUCTION 
  Dengue fever is now found in more than 100 developing 
countries. Carried by mosquitoes in tropical and sub-tropical 
areas, dengue virus causes two distinct disease states in 
humans: a mild disease called dengue fever (DF) and a much 
more severe disease called dengue hemorrhagic fever (DHF) 
which is potentially fatal. The World Health Organization 
has estimated that dengue virus annually causes 100 million 
new cases of DF, 500,000 cases of DHF, and 25,000 deaths 
[1, 2]. In total, 2.5 billion people are considered to be at risk 
for dengue infection. Originally endemic to Southeast Asia, 
since WWII dengue has spread around the globe to become 
endemic to all areas south of the 35th parallel, including 
Central and South America and Africa. Urbanization in the 
developing world has created dense living conditions, 
allowing the disease to spread more easily. At the moment, 
dengue has not spread significantly to North America, 
although it has already penetrated Hawaii and Florida. The 
astonishing speed with which dengue has spread across the 
rest of the world and the severity of its infection make 
dengue a prime threat to human life worldwide. 
Unfortunately, to date there are no effective vaccines or 
treatments against dengue [3]. 
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  Dengue infection presents itself in two modes: a primary 
and secondary infection. In primary infection, dengue enters 
target cells via  an uncharacterized primary receptor. 
Secondary infection occurs after inoculation generally with a 
different dengue serotype. In this case, dengue enters cells as 
a complex composed of the virus decorated with preexisting 
non-neutralizing antibodies. These immune complexes may 
enter host cells by interacting with alternate receptors such as 
Fc receptors, resulting in antibody-dependent enhancement 
of infection (ADE). ADE is hypothesized to contribute to the 
pathogenesis of severe dengue illness, as epidemiological 
studies have identified secondary infection as a risk factor 
for DHF and have shown that the presence of pre-existing 
anti-dengue antibodies correlates with DHF [4-13]. This 
biphasic manifestation of dengue infection greatly 
complicates vaccine development. 
  The identification of primary receptors for dengue would 
symbolize a major milestone in the development of anti-
dengue therapies. Indeed, by targeting the primary dengue 
receptor, we avoid the ADE biphasic manifestation of 
dengue infection, which represents a major obstacle in 
vaccine development. The identification of the primary 
receptors for dengue entry into a cell remains obscure. 
Several candidate molecules have been proposed to serve as 
receptors for dengue including heparan sulfate proteoglycans 
[14], DC-SIGN [15, 16] and unknown cell surface proteins 
[17, 18]. However, to date, the true functions of these 
receptors in dengue infection remain to be further explored. 
On one hand, these receptors may serve as true entry   
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receptors, which mediate fusion between viral and cellular 
membranes, a pre-condition for productive infection of 
enveloped viruses. On the other hand, these receptors may 
simply serve as attachment receptors, which promote virus 
adsorption and internalization, either leading to enhanced 
infection or to a dead-end infection (i.e., virus directed into 
abortive cellular compartments). Moreover, the identity of 
the cells, which support robust dengue replication in humans, 
also remains obscure. Several candidate cell populations 
have been proposed such as monocytes, B lymphocytes, 
Langerhans cells, dendritic cells and endothelial cells [4, 5, 
19-27]. However, the conclusive proof that one of these cell 
populations serves as the main source of virus in the body is 
still missing. The paucity of information about the identity of 
the primary receptors and the target cells that dengue 
exploits in vivo may arise from the paucity of adequate tools 
to accurately measure dengue attachment, entry and 
replication in human primary cells. To address this issue, we 
generated antibodies directed against the abundant structural 
capsid protein of dengue and used them to develop sensitive 
and accurate assays, which permit detection of dengue 
infection: an enzyme-linked immunosorbent assay (ELISA), 
an intracellular FACS staining assay (IFSA), and a 
fluorescent focus assay (FFA). 
2. MATERIALS AND METHODS 
2.1. Cells 
  African green monkey Vero cells and human 293T cells 
were grown in DMEM supplemented with 10% FBS, 
penicillin, streptomycin and glutamine at 37˚C in 10% CO2. 
Aedes albopictus C6/36 mosquito cells were maintained in 
EMEM containing Earl’s salts and non-essential amino acids 
supplemented with 10% FBS, penicillin, streptomycin and 
glutamine at 28˚C in 5% CO2. 
2.2. Viruses 
  Virus stocks of dengue-2 16681 [28] and TSV01 
(accession number AY037116) were produced as described 
previously [20] by inoculating monolayers of Vero or C6/36 
cells in 150 cm
2 flasks with 100 l of 1  10
6 FFU/ml virus 
stock in 5 ml complete medium. After 2 h, 15 ml of complete 
medium was added to infected cells. Seven days post-
infection, viral supernatants were collected, filtered through 
a 0.2 micron filter, adjusted to 20% FBS, aliquoted and 
stored at -80˚C. Viral titers in focus-forming units per 
milliliter (FFU/ml) were determined by focus-forming assay 
(FFA) titration in Vero cells. 
2.3. Anti-Dengue-2 Capsid Antibody Production 
  Monoclonal and polyclonal antibodies were produced by 
immunizing Balb/c mice and New Zealand rabbits with 
recombinant dengue-2 (PR-159S1 strain) capsid protein [29] 
(generous gift from R. Kuhn). Murine and rabbit anti-capsid 
IgG were purified using protein A beads. 
2.4. Western Blot Analysis 
  Viruses from filtered supernatants of infected Vero cells 
were purified through a 30% sucrose cushion by 
ultracentrifugation at 23,000 rpm in an SW28 rotor 
(Beckman) for 2.5 h at 4˚C. Pelleted viruses were lysed and 
loaded onto an SDS-gel together with recombinant dengue-2 
capsid as a positive control. Western blot analysis was 
performed according to manufacturer’s instruction for Tris-
Glycine precast minigels (Invitrogen). Blots were incubated 
with
 primary monoclonal or polyclonal anti-dengue-2 IgG (5 
g/ml) overnight, incubated with secondary horseradish 
peroxidase (HRP)-conjugated anti-mouse or -rabbit IgG for 
2 h at room temperature (Amersham) (1/10,000 dilution)
 and 
revealed by ECL (Perkin-Elmer). 
2.5. Dengue Replication Detected by Enzyme-Linked 
Immunosorbent (ELISA) 
  Cells (2 x 10
4) were infected with dengue at a 
multiplicity of infection (MOI) of 0.01 for 2 h at 37˚C, 
washed twice with medium, and incubated in 2 ml complete 
medium at 37˚C in 10% CO2. Supernatant aliquots were 
collected on days 0, 3, 5, 7 and 10 post-infection. Viruses 
were lysed by mixing supernatant with 0.5% NP-40 in PBS 
for 10 min at room temperature with vigorous shaking and 
frozen at -20˚C. 96-well plates coated overnight at 4˚C with 
rabbit anti-capsid dengue-2 IgG (20 g/ml) were washed 10 
times with H2O, blocked with 3% BSA in PBS for 1 h at 
room temperature, and washed 4 times with wash buffer 
(PBS containing 1% BSA and 0.02% Tween). Virus 
supernatants were added to ELISA plate for 2 h at room 
temperature. Wells were washed 10 times with washing 
buffer, incubated for 2 h at 4˚C with biotinylated rabbit or 
murine anti-capsid IgG (2 g/ml), washed 10 times, 
incubated for 30 min at room temperature in the dark with 
streptavidin-conjugated HRP (Jackson Laboratories and 
Immunochemicals) (1/1000 dilution) and washed 10 times 
with washing buffer. The o-phenylenediamine 
dihydrochloride substrate (Sigma-Aldrich) (100 l) was 
added to wells and reaction was stopped after addition of 
H2SO4 (4 N) (Fisher Scientific) (100 l). Plates were read at 
495 nm on a microplate reader (Molecular Devices). 
2.6. Dengue Replication Detected by Intracellular FACS 
Staining Assay (IFSA) 
  IFSA was conducted as described previously [30, 31] 
with minor modifications. Cells (2 x 10
5) were infected with 
dengue at an MOI of 0.1 for 2 h at 37˚C, washed twice with 
medium, and incubated in 2 ml complete medium at 37˚C in 
10% CO2. Three days post-infection, cells were washed, 
trypsinized, resuspended in PBS at 1  10
6/ml and fixed with 
0.2% paraformaldehyde in PBS for 30 min on ice. Cells were 
washed, permeabilized in PBS containing 0.2% Tween for 
15 min at 37˚C, washed and resuspended in FACS buffer 
(PBS containing 2% FBS). For intracellular staining, cells 
(10
5) were incubated for 30 min at 4˚C with 10 g/ml of 
isotype controls, mouse monoclonal anti-dengue capsid 9A7 
IgG, or mouse anti-dengue Env complex IgG (Chemicon). 
Cell permeabilization was confirmed by staining cells with 
mouse anti-tubulin IgG (Santa Cruz Biotechnologies). Cells 
were washed, incubated with secondary phycoerythrin (PE)-
conjugated anti-mouse IgG (10 g/ml) for 30 min at 4˚C, 
washed again, resuspended in PBS, fixed in 2% 
paraformaldehyde and stored at 4˚C until FACS analysis. 
2.7. Dengue Replication Detected by Fluorescent Focus 
Assay (FFA) 
  FFA was conducted as described previously [32, 33] with 
minor modifications. Briefly, Vero cells (1 x 10
4) seeded 
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containing viruses (dilutions from 10
-1 to 10
-6) for 2 h at 
37˚C, washed once and incubated for 72 h at 37˚C in 10% 
CO2. Cells were washed, fixed with 4% formaldehyde in 
PBS for 20 min at room temperature, washed again and 
permeabilized with PBS containing 3% BSA, 0.3% TritonX-
100 and 10% FBS for 1 h at room temperature. Cells were 
incubated with mouse monoclonal anti-dengue envelope or 
anti-capsid 9A7 IgG (1 g/ml) in 3% BSA and 0.3% Triton 
X-100 for 1 h at room temperature. Cells were washed 3 
times with PBS and incubated with Alexa555-conjugated 
anti-mouse IgG (Molecular Probes) (1/1000 dilution) for 1 h 
at room temperature. Cell nuclei were stained with Hoechst 
dye. Cells were washed 3 times, resuspended in PBS and 
analyzed for number of infectious foci by fluorescent 
microscope (Zeiss). 
2.8. RT-PCR 
  RT-PCR was performed to determine DENV replication 
by quantifying DENV-2 genomic RNA copies. Viral RNA 
was extracted using RNA extraction kit (QIAamp Viral RNA 
mini kit). RT-PCR assay was performed by adding 1 L of 
extracted viral RNA to the SensiMix SYBR green reagent, 
which contained 7.4 μL ddH2O, 10 μL 2x SensiMix One-
Step, 0.4 μL 50x SYBR Green solution, 10 U of RNAse 
Inhibitor, 50 pmoL of forward (DNF) and reverse (D2R) 
primers. All samples were assayed in triplicate. The 
amplifications were performed using the DNA Engine 
Opticon system (MJ Research/Bio-Rad, Hercules, CA) with 
the following thermal conditions: reverse transcription at 
50°C for 30 min, initial denaturation at 95°C for 10 min, 
followed by 45 cycles of 95°C for 15 sec, 59°C for 30 sec 
and 72°C for 30 sec. Melting curve analysis was 
subsequently performed at temperature from 60°C to 98°C to 
verify the assay specificity. For absolute quantitation of the 
viral RNA, a standard curve was established with a serially 
diluted RNA extracted from DEN-2 stock. 
2.9. Clinical Specimens 
  Forty serum samples were obtained from DEN-2 infected 
patients, who gave a positive result for anti-DEN-2 
antibodies. Ten serum samples from blood donors were 
collected as negative controls. 
3. RESULTS 
3.1. Production and Characterization of Anti-Dengue 
Capsid Antibodies 
  The development of assays, which rapidly and sensitively 
detect dengue attachment, entry and replication, is essential 
in order to identify the primary host cells and receptors that 
support viral replication in the host. To address this issue, we 
generated antibodies directed against the abundant structural 
capsid protein of dengue and developed enzyme-linked 
immunosorbent (ELISA), intracellular FACS staining 
(IFSA), and fluorescent focus (FFA) assays to detect dengue 
virus and infection. Balb/c mice and New Zealand rabbits 
were immunized with recombinant dengue-2 (PR-159S1 
strain) capsid core protein purified from E. coli [29]. We 
produced mouse monoclonal anti-dengue-2 capsid antibodies 
and rabbit polyclonal antisera. We analyzed by Western blot 
the reactivity of the antibodies toward dengue-2 capsid 
derived either from E. coli or from purified viruses. 
Recombinant capsid derived from the dengue-2 PR-159S1 
strain was purified from E. coli as described previously [29]. 
Dengue-2 16681 viruses were purified from supernatant of 
infected Vero cells by ultracentrifugation over a 30% sucrose 
cushion. Pelleted viruses were lysed and analyzed by 
Western blot. We found that both monoclonal (9A7) (Fig. 1, 
lane 2) and polyclonal (Fig. 1, lane 6) anti-dengue-2 capsid 
antibodies efficiently recognize recombinant dengue-2 
capsid (at around 10 kDa). Monoclonal (9A7) (Fig. 1, lane 4) 
and polyclonal (Fig. 1, lane 8) anti-dengue-2 capsid 
antibodies recognize a single band (around 12 kDa) in viral 
lysates, corresponding to capsid incorporated into dengue-2 
viruses. 
  The difference in size between recombinant and viral 
dengue-2 capsid proteins may result from post-translational 
modifications such as protein cleavage or phosphorylation. 
 
Fig. (1). Specificity of anti-dengue-2 capsid antibodies. E. coli-derived recombinant PR-159S1 dengue-2 capsid (lanes 2 and 6), purified 
dengue-2 16681 viruses (lanes 4 and 8) and supernatant of uninfected cells (mock virus) (lanes 3 and 7) were analyzed by Western blot using 
anti-dengue-2 capsid monoclonal (lanes 2 to 4) or polyclonal (lanes 6 to 8) antibodies. 
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No reactivity was observed in ultracentrifuged supernatant 
from uninfected Vero cells (mock) (Fig. 1, lanes 3 and 7). 
Moreover, no reactivity was observed toward other dengue 
serotypes such as dengue-1, -3 and -4 (data not shown). This 
demonstrates that our monoclonal and polyclonal antibodies 
recognize dengue-2 capsid specifically. 
3.2. Dengue-2 Replication Detected by Capsid ELISA 
  Using our monoclonal and polyclonal anti-dengue-2 
capsid antibodies, we developed a rapid, reproducible and 
sensitive ELISA. Briefly, 96-well plates were coated with 20 
g/ml of protein A-purified rabbit anti-capsid dengue-2 IgG, 
washed and blocked with 3% BSA. Increasing 
concentrations of recombinant dengue-2 capsid protein 
diluted in PBS containing 0.5% NP-40 were added to ELISA 
plates (triplicates). Captured dengue-2 capsid was detected 
with biotinylated mouse monoclonal anti-dengue-2 capsid 2 
g/ml IgG and streptavidin-conjugated HRP. The threshold 
of detection of recombinant dengue-2 capsid by the ELISA 
was 100 to 300 pg/ml (Fig. 2). 
 
Fig. (2). Recombinant dengue-2 capsid ELISA. 96-well plates 
were coated with 20 g/ml of rabbit anti-capsid dengue-2 IgG, 
washed and blocked with 3% BSA. Increasing concentrations of 
recombinant dengue-2 capsid diluted in PBS containing 0.5% NP-
40 were added to ELISA plates in triplicates. Captured capsid was 
detected with 2 g/ml of biotinylated monoclonal anti-dengue-2 
capsid IgG followed by streptavidin-conjugated HRP. The o-
phenylenediamine dihydrochloride substrate was added to wells and 
reaction was stopped. Plates were read at 495 nm on a microplate 
reader. Results are representative of five independent experiments. 
Error bars represent standard deviations (triplicates). 
  We then asked if our ELISA can detect dengue 
replication over time by measuring levels of capsid released 
into the supernatant of infected cells. Vero or 293T cells 
were infected with either 16681 or TSVO1 dengue-2 viruses 
at an MOI of 0.01. Supernatants from infected cells were 
collected at different time points and amounts of virus 
quantified by ELISA. Viral replication can be detected as 
early as 3 days post-infection and reaches a plateau between 
day 7 and 10. Note that if we increase the MOI, capsid 
release into supernatant of infected cells can already be 
detected 48 h post-infection (data not shown). We found that 
16681 replicates more robustly than TSV01 in both Vero and 
293T cells (Fig. 2). Specifically, 16681 reaches a growth 
peak of 30-40 ng/ml of capsid in supernatant of infected 
cells, whereas TSV01 reaches a growth peak of 5-15 ng/ml 
(Fig. 3). We obtained similar growths in human Huh-7 and 
mosquito C6/36 cells (data not shown). This demonstrates 
that our capsid ELISA permits rapid and sensitive detection 
of dengue replication in various cell lines. 
3.3. Dengue-2 Replication Detected by Intracellular 
FACS Staining Assay (IFSA) Using Anti-Capsid 
Antibodies 
  We then asked whether our ELISA is as accurate as other 
previously established assays, which measure dengue 
infection and replication. Specifically, we developed an 
intracellular FACS staining assay (IFSA) as well as a 
fluorescent focus assay (FFA) using anti-capsid antibodies. 
We then compared ELISA, IFSA and FFA for their 
capacities to monitor dengue infection in various cell lines. 
First, we developed an IFSA using anti-capsid antibodies. 
Vero cells (2 x 10
5) were infected with 16681 dengue-2 virus 
at an MOI of 0.1 for 2 h at 37˚C, washed twice and 
incubated in complete medium for three days. Cells were 
then washed, trypsinized, fixed and permeabilized. 
Permeabilized infected cells were incubated with the 
monoclonal anti-dengue capsid 9A7 antibody followed by a 
secondary phycoerythrin (PE)-conjugated anti-mouse 
antibody. Cells were then washed, fixed in 
paraformaldehyde and analyzed by FACS. Efficiency of 
permeabilization was verified by anti-tubulin staining. 
Ninety-five to 99% of the cells were positive for tubulin 
staining after permeabilization (Fig. 4, bottom panels), 
whereas less than 0.01% of the cells were positive for 
tubulin staining without permeabilization (data not shown). 
Importantly, we found that 75 to 80% of infected cells were 
positive after anti-dengue capsid 9A7 antibody staining (Fig. 
4, top right panel) compared to 0.03 to 0.07% of non-
infected cells (Fig. 4, top left panel). We obtained similar 
results using mouse anti-dengue envelope complex 
antibodies (Chemicon) (data not shown). Our data indicate 
that anti-dengue-2 capsid antibodies can be used to measure 
dengue replication by ELISA (Fig. 3) as well as by IFSA 
(Fig. 4). 
3.4. Inhibition of Dengue-2 Replication Detected by 
ELISA and IFSA Using Anti-Capsid Antibodies 
  In order to compare the accuracies of ELISA and IFSA, 
we tested them for their abilities to measure the potency of 
anti-dengue agents. Specifically, we compared side-by-side 
ELISA and IFSA capacities to detect inhibition of dengue-2 
infection by neutralizing antibodies. Vero cells were exposed 
to dengue-2 16681 virus at an MOI of 0.1 in the presence or 
absence of the neutralizing anti-dengue-2 envelope 3H5 
antibody (hybridoma supernatant diluted at 1/100, 1/1000 
and 1/10,000) (kindly provided by R. Kinney). Three days 
post-infection, infection was monitored either by IFSA, by 
measuring amounts of intracellular capsid, or by ELISA, by 
measuring amounts of capsid released in the supernatant. By 
IFSA, we found that the neutralizing 3H5 antibody 
efficiently reduces dengue-2 infection. The percentage of 
capsid positive Vero cells drastically decreases (60.5%, 
27.8% and 4.25% of positive cells) in the presence of 
increasing concentration of 3H5 antibody (Fig. 4). 
Specifically, we found that dengue-2 infectivity goes from 
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100 down to 76, 16 and 5.6% in the presence of 3H5 
hybridoma diluted at 1/10000, 1/1000 and 1/100, 
respectively. Importantly, we observed a very similar pattern 
of inhibition of dengue-2 replication by 3H5 when we 
quantified amounts of capsid released in the supernatant of 
infected cells by ELISA (Table 1, right column). Dengue-2 
infectivity monitored by ELISA is gradually reduced from 
100 to 75, 36 and 5.4% when 3H5 is added at a dilution of 
1/10000, 1/1000 and 1/100, respectively. These data indicate 
that ELISA and IFSA assays using anti-capsid antibodies 
represent accurate tools to measure dengue-2 replication as 
well as to evaluate the potency of anti-dengue agent 
candidates. 
 
Fig. (3). Detection of dengue-2 replication by ELISA. Vero and 293T cells were exposed to TSVO1 or 16681 dengue-2 virus at an MOI of 
0.01. Supernatants from infected cells were harvested on days 0, 3, 5, 7 and 10. Dengue capsid content in supernatant was quantified by 
ELISA as described above (Fig. 2). Results are expressed in ng of dengue-2 capsid per mL of supernatant of infected cells. Results are 
representative of two independent experiments. Error bars represent standard deviations (triplicates). 
Fig. (4). Detection of dengue-2 replication by intracellular FACS staining assay (IFSA). Vero cells were exposed to dengue-2 16681 
virus at an MOI of 0.1 preincubated for 1 h with the neutralizing anti-dengue-2 envelope 3H5 antibody (hybridoma supernatant diluted at 
1/100, 1/1000 and 10,000). Three days post-infection, cells were washed, trypsinized, fixed and permeabilized. Permeabilized cells were 
stained with monoclonal anti-dengue capsid 9A7, anti-tubulin or isotype control antibodies. Cells were washed, incubated with 
phycoerythrin-conjugated anti-mouse antibodies, washed again, fixed and analyzed by FACS. Results are expressed in % of fluorescent cells. 
Results are representative of three independent experiments. 
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Table 1.  Comparison Between ELISA and IFSA for Dengue-
2 Replication Detection 
 
 IFSA  ELISA 
virus + 3H5 1/100  5.4  5.6 
virus + 3H5 1/1000  36  16 
virus + 3H5 1/10000  75  76 
virus only  100  100 
Vero cells were exposed to dengue-2 16681 virus at an MOI of 0.1 in the presence or absence 
of the neutralizing anti-dengue-2 envelope 3H5 antibody (hybridoma supernatant diluted at 
1/100, 1/1000 and 10,000). Three days post-infection, amounts of dengue-2 capsid in the 
supernatant were quantified by ELISA, while amounts of dengue-2 capsid in infected cells 
were quantified by IFSA. Results are expressed in percentage of infection by fixing dengue-2 
infection in the absence of neutralizing 3H5 antibody at 100. Results are representative of 
three independent experiments. 
3.5. Detection of Dengue-2 Replication by Fluorescent 
Focus Assay (FFA) Using Anti-Capsid Antibodies 
  We then developed an FFA using anti-capsid antibodies 
to compare its potential to measure dengue infection with 
that of ELISA and IFSA described above. FFA was 
conducted as described previously [32-33] with minor 
modifications. Briefly, supernatants from Vero and 293T 
cells infected with 16681 dengue-2 virus were harvested on 
days 0, 3, 5, 7 and 10 and immediately used to infect naïve 
Vero cells. Infected Vero cells were washed, fixed with 
formaldehyde and permeabilized with TritonX-100. Cells 
were then incubated with monoclonal anti-dengue-2 capsid 
or anti-envelope antibodies. Cells were washed and 
incubated with Alexa555-conjugated anti-mouse antibodies. 
Fig. (5). Detection of dengue-2 replication by fluorescent focus assay (FFA). A. Vero cells were infected with 16681 dengue-2 virus for 1 
h at 37˚C, washed and incubated for three days. Cells were washed, fixed with formaldehyde and permeabilized with TritonX-100. Cells 
were then incubated with monoclonal anti-dengue-2 capsid 9A7 (bottom panels) or anti-dengue-2 envelope complex antibodies (middle 
panels). Cells were washed and incubated with Alexa555-conjugated anti-mouse antibodies. Cell nuclei were stained with Hoechst dye (top 
panels). Cells were washed and analyzed for infectious foci using a fluorescent microscope. B. Vero and 293T cells were infected with 
16681 dengue-2 virus as described in Fig. (3). Supernatants from infected cells were harvested on day 0, 3, 5, 7 and 10 and immediately used 
to infect naïve Vero cells. Detection of dengue-2 replication in Vero cells was quantified by fluorescent focus assay as described in A using 
either anti-capsid or anti-envelope antibodies. Results (duplicates) are expressed in number of focus-forming units (FFU)/ml. Results are 
representative of two independent experiments. C. Vero cells were infected with 16681 dengue-2 virus at an MOI of 0.01. At days 0, 3, 5 and 
7, supernatants and cells were collected for capsid ELISA and FFA analyses using anti-capsid antibodies. Results (duplicates) are expressed 
either in ng of capsid per mL of supernatant or in number of focus-forming units (FFU) per mL of supernatant. Results are representative of 
two independent experiments. D. Real-time PCR to measure DEN-2 RNA levels. Results are representative of two independent experiments. 
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Infectious foci were visualized using a fluorescent 
microscope. 
  We found that the subcellular localization of capsid and 
envelope in infected Vero cells greatly differs (Fig. 5A). The 
anti-capsid antibody mainly stains the nucleus and nucleolus 
(Fig. 5A, bottom panels), whereas the anti-envelope complex 
antibody stains the cytoplasm (Fig. 5A, top panel). This is in 
accordance with previous studies, which showed that capsid 
localizes in the nuclear compartment [34, 35]. Importantly, 
dengue-2 replication monitored by FFA using the anti-capsid 
antibody perfectly correlates with that using the anti-
envelope antibody (Fig. 5B). More importantly, dengue-2 
replication monitored by FFA using anti-capsid antibodies 
perfectly correlates with that using our capsid ELISA and 
FFA (Fig. 5C). RT-PCR analysis of dengue-2 replication 
match well the capsid ELISA data, although there is a small 
window period between when viral RNA is detectable by the 
sensitive RT-PCR and when capsid is detected by ELISA 
(Fig.  5D). Altogether these data indicate that antibodies 
directed against the structural capsid protein of dengue-2 
represent ideal tools to measure dengue-2 replication in 
various detection assays. 
3.6. Detection of Dengue-2 Capsid in Patient Sera by ELISA 
  We then asked whether this capsid ELISA can be used as 
a diagnostic tool to identify infected patients. Specifically, 
we collected 10 donor sera and 50 dengue-2 patient sera and 
tested them for capsid content by ELISA. Importantly, we 
constantly found that patient sera gave capsid values superior 
to those of donor sera (Table 2). This demonstrates that the 
capsid ELISA assay could be of a great utility for screening 
Dengue 2 infected  patients.  It also suggests that similar 
assays can be developed when similar antibodies will be 
generated for the detection of the 3 other serotypes. 
DISCUSSION 
  In this study, we produced monoclonal and polyclonal 
antibodies directed against the structural capsid protein of 
dengue-2. The antibodies recognize capsid specifically since 
no cross-reactivity was observed by Western blot toward 
other viral or cellular proteins. Moreover, no cross-reactivity 
was observed toward capsids derived from other serotypes 
such as dengue-1, -3 and -4. We then developed an ELISA 
for dengue-2 capsid. We showed that the ELISA allows 
rapid and sensitive (ng/mL range) detection of dengue-2 
(i.e., 16681 and TSVO1) replication in various cell lines 
including human and mosquito cells. We then compared the 
accuracy of the ELISA to measure dengue-2 replication with 
that of other previously established assays. Specifically, we 
developed an IFSA as well as an FFA using anti-capsid 
antibodies. Importantly, we found that kinetic and peak 
amplitude of dengue-2 replication detected by ELISA 
correspond perfectly with those measured by IFSA or FFA. 
Although a couple of studies also generated anti-dengue 
capsid antibodies [34-35], to our knowledge, this is the first 
demonstration that anti-capsid antibodies represent valuable 
tools to measure dengue virus infection using various assays 
including ELISA, IFSA and FFA. 
  There are several advantages for using a capsid ELISA to 
detect dengue infection. The ELISA is a rapid test that can  
 
Table 2.  Dengue 2 Capsid Detection in Serum 
 
# Serum  pg/mL of  
DEN-2 Capsid 
# Serum  pg/mL of  
DEN-2 Capsid 
1  0  21  266 +/- 14 
2  0  22  126 +/- 6 
3  0  23  199 +/- 8 
4  0  24  75 +/- 5 
5  0  25  304 +/- 16 
6  0  26  226 +/- 14 
7  0  27  98 +/- 7 
8  0  28  137 +/- 9 
9  0  29  206 +/- 11 
10  00k  30  277 +/- 14 
    31  173 +/- 3 
1  187 +/- 9  32  196 +/- 6 
2  99 +/- 6  33  263 +/- 16 
3  233 +/- 18  34  227 +/- 11 
4  115 +/- 9  35  374 +/- 13 
5  88 +/- 4  36  86 +/- 4 
6  337 +/- 25  37  156 +/- 7 
7  288 +/- 14  38  199 +/- 3 
8  107 +/- 7  39  233 +/- 17 
9  166 +/- 8  40  273 +/- 15 
10  121 +/- 9  41  144 +/- 6 
11  186 +/- 12  42  181 +/- 7 
12  244 +/- 18  43  244 +/- 12 
13  278 +/- 8  44  270 +/- 11 
14  311 +/- 13  45  295 +/- 14 
15  89 +/- 5  46  352 +/- 17 
16  164 +/- 8  47  95 +/- 5 
17  195 +/ 6  48  173 +/- 11 
18  266 +/- 18  49  263 +/- 15 
19  298 +/- 12  50  143 +/- 8 
20  144 +/- 7     
Donor sera (yellow cells) and dengue 2 patient sera (green cells) were analyzed for 
dengue 2 capsid content by ELISA. Samples were diluted at 1/100. Results (triplicate) 
are representative of two independent experiments. 
 
be completed in a few hours. It thus represents an ideal 
alternative assay for the time-consuming standard plaque 
assay. The 96-well format ELISA test is a very qualitative 
tool that permits the analysis of a large number of samples in 
duplicate or triplicate. The capsid ELISA is thus extremely 
convenient to measure growth of numerous dengue-2 strains 
in several cell types over a long period of time (2-3 weeks) 
or to screen a large panel of anti-dengue compound 
candidates. In contrast to the plaque assay, the ELISA does  36    The Open Virology Journal, 2012, Volume 6  Selvarajah et al. 
not rely on virus-induced cytopathic effects and thus can be 
used in a broader range of target cells or mutant viruses that 
do not form plaques. Another advantage of using a capsid 
ELISA to detect dengue infection is that accumulation of 
capsid into the supernatant of infected cells (peak growth) 
represents a reliable proof of replication. In contrast, positive 
intracellular stainings of viral proteins by IFSA or FFA may 
result from dengue capture and internalization by attachment 
receptors (i.e., heparan sulfate proteoglycans or lectins) in 
the absence of true productive infection (without fusion 
between the viral and the cellular membrane). Moreover, 
IFSA and FFA procedures are more time-consuming than 
ELISA procedures, mainly when a large number of samples 
need to be analyzed. A major advantage of the capsid ELISA 
is that it detects viruses independently of their infectious 
capacities. This is extremely important for studies proposing 
to identify regions or residues of the viral envelope 
necessary for infection. Indeed, envelope mutant viruses 
released into the supernatant of transfected cells can be 
standardized for capsid content by ELISA and subsequently 
tested for infection by IFSA or FFA. Similarly, the capsid 
ELISA will be extremely useful to map the domains or 
residues of the structural capsid protein necessary for 
dengue-2 infection. The capsid ELISA also represents an 
ideal tool to analyze several steps of the dengue life cycle 
because it permits the quantitative measure of amounts of 
viruses, which are released from infected cells (viral 
budding), which are attached onto the surface of a cell (viral 
attachment), or which entered into the cell (viral 
internalization). 
  In conclusion, we developed an ELISA for capsid that 
allows rapid, sensitive and specific detection of dengue-2 
replication in human and mosquito cells. We demonstrated 
that the capsid ELISA is as accurate as other established 
infection assays such as IFSA and FFA. The capsid ELISA 
may not only represent a useful tool for in vitro basic 
research, but it may also represent a valuable diagnostic tool 
for dengue detection in clinical patients in epidemic 
conditions. Prospective studies should be carried out to 
confirm the clinical value of this new test. 
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